Talis Biomedical Corp financial data

Location
Chicago, IL
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2024 - 19 Aug 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 866 % -23.2%
Debt-to-equity 39.5 % +43%
Return On Equity -79.7 % -12.8%
Return On Assets -57.2 % -3.16%
Operating Margin -13.5K % -327%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31.7M shares +732%
Common Stock, Shares, Outstanding 1.82M shares +0.17%
Entity Public Float 8.15B USD +11%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 1.82M shares +0.28%
Weighted Average Number of Shares Outstanding, Diluted 1.82M shares +0.28%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 408K USD -85.7%
Research and Development Expense 20.5M USD -64.1%
Costs and Expenses 55.5M USD -40.4%
Operating Income (Loss) -55.1M USD +38.9%
Net Income (Loss) Attributable to Parent -51M USD +40.5%
Earnings Per Share, Basic -28 USD/shares +56.6%
Earnings Per Share, Diluted -28 USD/shares +56.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 59.9M USD -39%
Assets, Current 63.6M USD -37.6%
Property, Plant and Equipment, Net 425K USD -88%
Operating Lease, Right-of-Use Asset 7.91M USD -50.7%
Other Assets, Noncurrent 766K USD -50.3%
Assets 72.7M USD -40.9%
Accounts Payable, Current 3.79M USD +52.1%
Accrued Liabilities, Current 634K USD -32.4%
Liabilities, Current 8.2M USD -11.5%
Operating Lease, Liability, Noncurrent 15.9M USD -10%
Liabilities 24.1M USD -10.5%
Retained Earnings (Accumulated Deficit) -562M USD -9.99%
Stockholders' Equity Attributable to Parent 48.6M USD -49.4%
Liabilities and Equity 72.7M USD -40.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.43M USD +61%
Net Cash Provided by (Used in) Financing Activities 2K USD -93.9%
Net Cash Provided by (Used in) Investing Activities 30K USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 1.82M shares +0.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.4M USD +61.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 60.6M USD -39.8%
Deferred Tax Assets, Valuation Allowance 161M USD +14.5%
Deferred Tax Assets, Gross 164M USD +11.2%
Operating Lease, Liability 18.8M USD -7.78%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 23.4M USD -10.8%
Property, Plant and Equipment, Gross 16M USD +5.44%
Operating Lease, Liability, Current 2.92M USD +6.84%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.14M USD +5.86%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.06M USD +126%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure -14.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.64M USD -21.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.24M USD +5.89%
Deferred Tax Assets, Operating Loss Carryforwards 81.7M USD +22.5%
Unrecognized Tax Benefits 10.3M USD +15.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.33M USD +5.88%
Deferred Tax Assets, Net of Valuation Allowance 3.67M USD -50.9%
Share-based Payment Arrangement, Expense 3.48M USD -28%